​

Enliven Therapeutics Ownership | Who Owns Enliven Therapeutics?

OverviewForecastFinancialsChart

Enliven Therapeutics Ownership Summary

Enliven Therapeutics is owned by 38.69% institutional investors, 5.56% insiders, and 55.75% retail investors. Orbimed advisors is the largest institutional shareholder, holding 15.96% of ELVN shares.

ELVN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockEnliven Therapeutics38.69%5.56%55.75%
SectorHealthcare Stocks 279.19%10.58%-189.76%
IndustryBiotech Stocks 63.97%10.68%25.35%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Orbimed advisors7.96M15.96%$156.64M
Commodore capital lp4.67M9.38%$92.00M
Vr adviser4.03M8.08%$79.24M
Ra capital management848.99K1.70%$16.71M
First turn management535.09K1.07%$10.53M
Ikarian capital289.54K0.58%$5.70M
Acuta capital partners265.27K0.53%$5.22M
Cormorant asset management, lp250.00K0.50%$4.92M
Millennium management132.89K0.27%$2.62M
Stempoint capital lp120.43K0.24%$2.37M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Commodore capital lp4.67M6.78%$92.00M
Vr adviser4.03M6.74%$79.24M
Acuta capital partners265.27K6.05%$5.22M
Orbimed advisors7.96M3.75%$156.64M
First turn management535.09K2.12%$10.53M
Stempoint capital lp120.43K0.76%$2.37M
Ikarian capital289.54K0.70%$5.70M
Cormorant asset management, lp250.00K0.37%$4.92M
Ra capital management848.99K0.28%$16.71M
Sofinnova investments33.55K0.04%$660.21K

Top Buyers

HolderShares% AssetsChange
Commodore capital lp4.67M6.78%470.00K
Millennium management132.89K0.00%82.08K
Jane street group27.38K0.00%27.38K
Stempoint capital lp120.43K0.76%23.71K
Tudor investment corp et al13.36K0.00%13.36K

Top Sellers

HolderShares% AssetsChange
Nicholas investment partners, lp---157.63K
Ikarian capital289.54K0.70%-105.00K
Artia global partners lp---102.90K
Soleus capital management---75.41K
Verition fund management---24.89K

New Positions

HolderShares% AssetsChangeValue
Tudor investment corp et al13.36K0.00%13.36K$262.98K

Sold Out

HolderChange
Srs capital advisors-103.00
Capital advisors-302.00
Virtus etf advisers-3.09K
Brevan howard capital management lp-10.14K
Legato capital management-13.49K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202514-87.27%19,292,189-60.47%380.38%5-92.19%3-88.00%
Dec 31, 20241129.80%49,623,7144.06%1021.05%6611.86%254.17%
Sep 30, 20241028.51%47,688,348-1.31%980.98%59-14.49%2484.62%
Jun 30, 20249430.56%48,320,2788.69%1000.90%6972.50%13-40.91%
Mar 31, 20247218.03%44,456,33613.99%1051.18%4029.03%2269.23%

Recent Insider Transactions

DateNameRoleActivityValue
Jun 03, 2025Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICERSell$150.22K
Jun 03, 2025Kintz Samuel PRESIDENT AND CEOSell$150.35K
May 27, 2025Hohl Benjamin CHIEF FINANCIAL OFFICERSell$52.59K
May 19, 2025Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICERSell$81.53K
May 19, 2025Kintz Samuel PRESIDENT AND CEOSell$82.45K

Insider Transactions Trends

DateBuySell
2025 Q2-20
2025 Q1-14
2024 Q4-34
2024 Q3-27
2024 Q2-49

ELVN Ownership FAQ

Who Owns Enliven Therapeutics?

Enliven Therapeutics shareholders are primarily institutional investors at 38.69%, followed by 5.56% insiders and 55.75% retail investors. The average institutional ownership in Enliven Therapeutics's industry, Biotech Stocks , is 63.97%, which Enliven Therapeutics falls below.

Who owns the most shares of Enliven Therapeutics?

Enliven Therapeutics’s largest shareholders are Orbimed advisors (7.96M shares, 15.96%), Commodore capital lp (4.68M shares, 9.38%), and Vr adviser (4.03M shares, 8.08%). Together, they hold 33.42% of Enliven Therapeutics’s total shares outstanding.

Does Blackrock own Enliven Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Enliven Therapeutics.

Who is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested?

Commodore capital lp is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested, with 6.78% of its assets in 4.68M Enliven Therapeutics shares, valued at 92M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools